New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For GOOG;EMC;VMW;INTC;GILD;FRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 >>
August 31, 2015
06:24 EDTGOOGCCI charges Google with abusing market dominance, Economic Times reports
The Competition Commission of India is charging Google (GOOG) with abusing its dominant market position by rigging search results, a claim corroborated by Flipkart, Facebook (FB), Nokia's (NOK) maps division, MakeMy-Trip.com (MMYT), and several other companies, the Economic Times reports. The case marks the first globally where an antitrust body is formally raising such charges against Google, the report says. CCI might impose a fine of up to 10% of Google's income, the report says. Reference Link
06:10 EDTGOOGBanks lobby EU over privacy rules overhaul, FT reports
Subscribe for More Information
August 30, 2015
21:03 EDTGOOGGoogle adds home service professionals to search results, WSJ says
Subscribe for More Information
19:52 EDTGOOGApple ad blocker poses challenge for publishers, Google, WSJ says
Apple's (AAPL) forthcoming iOS 9 mobile operating system will allow users to download ad blocking software, potentially posing a threat to digital publishers as well as Google's (GOOG) massive advertising business, reports the Wall Street Journal. "Apple is going to create a massive consumer appetite for blocking ads," anti-ad blocking firm PageFair's CEO Sean Blanchfield told the publication. Reference Link
14:47 EDTGOOGGoogle shares could see 20% upside, Barron's says
Shares of Google still have 20% upside as the company's financials improve and YouTube continues to grow, Barron's contends in its 'Follow Up' column. Google's recent financial results have shown an uptick in revenue growth as well as reduced growth in both costs and head count, Barron's says, adding that Goldman Sachs' recent $800 price target looks "plenty feasible." Reference Link
14:22 EDTGOOGSecular growth stocks look attractive amid market volatility, Barron's says
Subscribe for More Information
12:33 EDTINTCDividend-rich blue chips look attractive amid market volatility, Barron's says
Subscribe for More Information
August 28, 2015
16:00 EDTINTCOptions Update; August 28, 2015
iPath S&P 500 VIX Short-Term Futures up 2.06 to 26.77 Option volume leaders: AAPL FB BAC FCX NFLX RIG INTC TSLA CVX
07:12 EDTGOOGWilliam Blair names 21 stocks best positioned for volatile markets
Subscribe for More Information
August 27, 2015
14:39 EDTGOOGGoogle volatility elevated on wide price movement
Subscribe for More Information
11:44 EDTGOOGGoogle says EC's Statement of Objections 'incorrect'
Subscribe for More Information
06:19 EDTINTCIntel Capital invests over $60M in Yuneec Holding
Subscribe for More Information
05:53 EDTINTCIC demand for notebooks picking up, DigiTimes reports
Subscribe for More Information
August 26, 2015
18:16 EDTGOOGGoogle still looks attractive, Barron's says
Subscribe for More Information
17:58 EDTGOOGAndroid Pay not launching this week, TechCrunch says
Google's (GOOG) Android Pay -- a mobile payment service set to compete with Apple's (AAPL) Apple Pay platform -- will not be launching this week despite various reports to the contrary, says TechCrunch, citing sources familiar with Google's plans. Reference Link
17:06 EDTGILDGilead AMBITION study results published in New England Journal of Medicine
Gilead Sciences (GILD) announced detailed results from the AMBITION study. In AMBITION, conducted in collaboration with GlaxoSmithKline (GSK), combination therapy with Letairis and tadalafil reduced the risk of clinical failure by 50% compared to the pooled Letairis and tadalafil monotherapy arm. These data were published in The New England Journal of Medicine. Letairis, a selective endothelin type-A receptor antagonist, and tadalafil, a PDE5 inhibitor, are each approved in the United States, the European Union and other countries as once-daily treatments for patients with pulmonary arterial hypertension with WHO/NYHA functional class II and III symptoms. Letairis is indicated in the U.S. to improve exercise ability and delay clinical worsening and in the EU under the tradename Volibris to improve exercise capacity. Tadalafil 40 mg is indicated in the U.S. and the EU to improve exercise ability and capacity, respectively. Preclinical data have suggested these therapies may have synergistic effects. However, combination use with Letairis and tadalafil is currently not approved.
16:26 EDTGOOG, EMC, VMWOn The Fly: Top stock stories for Wednesday
Subscribe for More Information
16:12 EDTVMWVMware names Ray O'Farrell Chief Technology and Development Officer
Subscribe for More Information
15:27 EDTVMW, EMCVMware falls after report EMC board weighing downstream merger proposal
Subscribe for More Information
12:47 EDTVMW, EMCOn The Fly: Top stock stories at midday
Subscribe for More Information
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use